Global Metastatic Prostate Cancer Treatment Market Size, Share, Analysis, Applications, Growth Insight, and Future Forecast – 2028

The global metastatic prostate cancer treatment market is anticipated to grow at a significant CAGR of 3.6% during the forecast period (2022-2028). Prostate cancer is a kind of cancer in which abnormal cells in the prostate gland proliferate and expand uncontrollably. Radiation, surgery, chemotherapy, biological therapy, and hormone therapy are all options for treating prostate cancer. Prostate cancer is treated and managed with a variety of diagnostic and therapeutic items, including prostatic adenocarcinoma, benign prostatic hyperplasia, small cell carcinoma, and others.

Some major factors driving the growth of the metastatic prostate cancer treatment market include rising prevalence of prostate cancer, rising public awareness about timely diagnosis and treatment of prostate cancer, increased R&D investment by drug innovators, strong drug development pipeline, and the availability of new prostate cancer treatments. Hormonal therapies, including non-metastatic castration-resistant (nmCRPC) and metastatic hormone naïve (mHNPC) are now preferably used for prostate cancer treatment.

The application of breakthrough technologies in screening and diagnostic testing is projected to drive the growth of market. Multiparametric MRI (MP-MRI) can significantly improve tumor detection while also establishing whether tissue biopsy is necessary or not. Several generic drugs are expected to enter the market as patents on significant current products are expiring during the forecast period.

Amongst application segment, hospitals hold the major share in the market as it is a most trusted and affordable source of cancer treatment. Medical insurance provided by some of the hospitals with cashless hospital visits is another factor driving the growth of this segment.

Asia-Pacific represents lucrative opportunities for the key players operating in the metastatic prostate cancer treatment market, owing to rising awareness about timely diagnosis and treatment of prostate cancer and rise in adoption of prostate cancer treatment products. Moreover, improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, developing R&D sector, and medical tourism are further contributing considerably to the market growth in Asia-Pacific region.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Treatment Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., and F. Hoffmann-La Roche AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Metastatic Prostate Cancer Treatment Market Report by Segment

By Treatment Type

• Chemotherapy
• Biological Therapy
• Hormone Therapy

By Application

• Hospitals
• Clinics
• Others

Global Metastatic Prostate Cancer Treatment Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa